Vasomune

3 articles with Vasomune

• Vasomune Announces Government Financial Support for the Development of COVID-19 Therapeutic

  11/8/2021

  Vasomune Receives a US $6.4 Million PRMRP Grant from the US Department of Defense and up to $2.8 Million from NRC IRAP to Support the Development of AV-001 for the Treatment of Patients with Severe COVID-19 Disease and COVID-associated ARDS

• Vasomune Announces Preliminary Positive Phase 1 Clinical Trial Results for Vascular Normalization Therapy

  3/25/2021

  AV-001 was Safe and Well-Tolerated in Healthy Volunteers Vasomune plans to initiate a Phase 2a proof-of-concept study following review with FDA to assess safety and efficacy in patients with severe COVID-19 disease

• Vasomune Therapeutics Announces Initiation of the First-in-Human Clinical Trial of a Potential Vascular Normalization COVID-19 Treatment

  12/17/2020

  First subjects have been dosed in Phase 1 study of AV-001, a novel first-in-class therapeutic Should the Phase 1 results show AV-001 is safe and well-tolerated, Vasomune will initiate a Phase 2 proof-of-concept study to assess efficacy in patients with moderate-to-severe COVID-19 disease